A Novel HDAC6 Inhibitor Enhances the Efficacy of Paclitaxel Against Ovarian Cancer Cells
Ovarian cancer cells overexpress HDAC6, and selective HDAC6 inhibitors have been considered potential new drugs for ovarian cancer either alone or in combination with other anticancer agents. We screened 46 potential novel HDAC6 inhibitors in ES-2 ovarian cancer cells and showed that compound <b&...
Saved in:
| Main Authors: | An-Jui Chi, Jui-Ling Hsu, Yun-Xin Xiao, Ji-Wang Chern, Jih-Hwa Guh, Chao-Wu Yu, Lih-Ching Hsu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/30/13/2793 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation
by: Ching Lin, et al.
Published: (2025-12-01) -
Exploring tubulin-paclitaxel binding modes through extensive molecular dynamics simulations
by: Marine Bozdaganyan, et al.
Published: (2025-03-01) -
Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
by: A. G. Kedrova, et al.
Published: (2019-11-01) -
Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases
by: Maria A. Theodoropoulou, et al.
Published: (2024-12-01) -
Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia
by: Haeun Yang, et al.
Published: (2025-07-01)